Wave to seek approval of Duchenne drug after mid-stage study data

Wave to submit Duchenne drug for approval after Phase 2 success

The results set the stage for a new therapeutic option for patients with the rare disease, which primarily affects young boys.

Wave Life Sciences Shakes Medical Field with Promising DMD Drug Trials - Real News Now

The burgeoning MAHA initiative is inspiring both federal and state governments throughout the United States. At the forefront is an RNA-based therapy developed by Wave Life Sciences, creating ripples in the field of medical science. This novel drug has shown efficacy in increasing dystrophin production and enhancing muscle function. A group of 11 patients suffering from Duchenne muscular dystrophy, linked to a mutation in exon 53, experienced si…

Wave to seek approval of Duchenne drug after mid-stage study data

The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.

Northern Minnesota boy is first American to receive groundbreaking treatment for muscular dystrophy

An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.

Medical student’s research to raise awareness of life-limiting condition

University of Plymouth news: Fifth-year medical student Ahsan Ali has published a review article into a genetic condition, Duchenne's Muscular Dystrophy (DMD).

Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531

Early results from Wave's ongoing DMD Phase II trial saw a decline in muscle necrosis and inflammation in the trial consisting of 11 boys with DMD.The post Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531 appeared first on Clinical Trials Arena.